Form 4: Guardant Health CMO's Equity Transactions

Guardant Health's Chief Medical Officer, Craig Eagle, reported multiple equity transactions including RSU vestings and shares withheld for tax obligations.

Summary

• Craig Eagle, Chief Medical Officer of Guardant Health, Inc., reported multiple equity transactions on January 1, 2026, as detailed in a Form 4 filing.
• These transactions included the acquisition of 25,448 shares of Common Stock through the vesting of various Restricted Stock Units (RSUs) and Performance-Based Restricted Stock Units (PBRSUs) at an exercise price of $0.
• Concurrently, 11,522 shares of Common Stock were disposed of (withheld by the company) at a price of $102.14 per share to cover tax withholding obligations related to the RSU vestings.
• Following these reported transactions, Craig Eagle's direct beneficial ownership of Guardant Health Common Stock increased to 58,927 shares.
• The filing also details the vesting schedules for several RSU and PBRSU awards, with future vesting dates extending to January 1, 2027.

Sentiment

Score: 5

Explanation: The filing reports routine equity compensation transactions for an executive, including vesting of restricted stock units and shares withheld for tax purposes. This is a standard occurrence and does not inherently indicate positive or negative sentiment about the company's performance or future prospects.

Positives

• The vesting of 25,448 shares from various RSU and PBRSU awards indicates the achievement of performance metrics for some awards and the passage of time for others, reflecting successful compensation milestones.
• The increase in direct beneficial ownership to 58,927 shares (after tax withholding) demonstrates continued equity alignment of the Chief Medical Officer with the company's performance and shareholder interests.

Negatives

• 11,522 shares of Common Stock were withheld by the company at a price of $102.14 per share to satisfy tax obligations, reducing the net shares received by the officer from the vesting events.

Future Outlook

The filing indicates future vesting events for various equity awards, with remaining installments for Restricted Stock Units and Performance-Based Restricted Stock Units scheduled to vest over the next two years, extending to January 1, 2027.

Industry Context

This Form 4 filing is a routine disclosure of insider equity transactions, common across all publicly traded companies. It reflects the standard practice of compensating executives with equity, aligning their interests with long-term shareholder value. It does not provide specific insights into broader industry trends or competitive positioning.

Related Party Transactions

• The reported transactions involve the vesting of equity awards (Restricted Stock Units and Performance-Based Restricted Stock Units) granted by Guardant Health, Inc. to its Chief Medical Officer, Craig Eagle, and the subsequent withholding of shares by the company to satisfy tax obligations related to these awards. These are compensation-related dealings between the company and an executive officer.

Stakeholder Impact

• Shareholders: The transactions represent a routine aspect of executive compensation, aligning management's interests with long-term company performance through equity ownership. The disposition of shares for tax purposes is a common practice and does not reflect a discretionary sale.
• Employees (Executive): The Chief Medical Officer's equity stake has increased, reinforcing his financial interest in the company's success.

Next Steps

• Remaining 75% of the Restricted Stock Unit award granted on November 7, 2022, will vest in equal quarterly installments over the remaining three-year period after October 1, 2023.
• Remaining 67% of the Restricted Stock Unit award granted on December 13, 2023, will vest in equal quarterly installments over the remaining two-year period after October 1, 2024.
• Remaining 34% of the Performance-Based Restricted Stock Unit award granted on February 26, 2024, will vest on January 1, 2027.
• Remaining 67% of the Restricted Stock Unit award granted on November 8, 2024, will vest in equal quarterly installments over the remaining two-year period after October 1, 2025.

Key Dates

Keywords

Guardant Health, GH, Craig Eagle, Form 4, Insider Transaction, Restricted Stock Units, Performance-Based RSUs, Equity Compensation, Beneficial Ownership, Officer Transactions